Koers NuOncology Labs, Inc. Other OTC
Aandelen
NLAB
US67057T1079
Bouw & Techniek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 156 mln. 146 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | - 0 | Nettowinst (verlies) 2022 | - 0 | EV/omzet 2021 * | - |
Nettoliquiditeiten 2021 * | - 0 | Nettoschuld 2022 | 41,88K 39,1K | EV/omzet 2022 | - |
K/w-verhouding 2021 * |
-
| K/w-verhouding 2022 |
-2.229
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 0% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yan-Ping Sheng
CEO | Chief Executive Officer | 63 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Yan-Ping Sheng
CEO | Chief Executive Officer | 63 | - |
Sunny Sukardi
CHM | Chairman | 59 | 31-01-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-13,47% | 59,76 mld. | |
+0,63% | 58,53 mld. | |
+17,74% | 37,2 mld. | |
+10,40% | 30,41 mld. | |
+9,81% | 28,4 mld. | |
+14,79% | 20,75 mld. | |
+14,69% | 19,41 mld. | |
+33,62% | 17,22 mld. | |
+69,47% | 17,16 mld. |